checkAd

     291  0 Kommentare Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP Immunomodulation

    -- 2020 award open for entries for a chance to win €50,000 --

    -- Investigator Award recognises individuals making a difference and reinforces company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications --

    STAINES-UPON-THAMES, United Kingdom, Oct. 22 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, has announced that its 2020 Advancing Extracorporeal Photopheresis (ECP) Immunomodulation Investigator Award is open for entries.

    Mallinckrodt logo

    As in previous years, the award is intended to recognise and support the institutions of those individuals who are making a difference in advancing the knowledge around ECP Immunomodulation in the EMEA region. With the winning entry receiving an educational grant of €50,000, this year's award programme supports research that investigates the overarching immunomodulatory role of ECP through inflammation control and resolution while specifically preserving immune function.

    The award, now in its third year, was developed by Mallinckrodt to mark 30 years of its pioneering THERAKOS ECP Immunomodulation. The Investigator Award reflects the company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications. The call for entries is now open and will take submissions until the closing date of 31 January 2020.

    "As a pioneer in ECP immunomodulation, Mallinckrodt established the ECP Immunomodulation Investigator Award to recognise the efforts of those working in this exciting field of medicine. I urge those involved in ECP Immunomodulation to submit an entry and so help further the understanding of immunomodulatory therapy through ECP", said Steven Romano, M.D., Executive Vice President and Chief Scientific Officer of Mallinckrodt.

    Last year's winning entry was submitted by Dr. Rachel Crossland of Newcastle University in the United Kingdom. Her team is investigating the impact of ECP Immunomodulation on extracellular vesicles and their profiles in response to therapy in patients with graft-versus-host disease (GvHD). A major complication affecting between 40-70% of Hematopoietic Stem Cell Transplant (HSCT) patients, severe GvHD carries a high mortality rate.1

    Seite 1 von 2


    PR Newswire (engl.)
    0 Follower
    Autor folgen

    Verfasst von PR Newswire (engl.)
    Mallinckrodt Announces Launch of 2020 Award in Support of Advancing ECP Immunomodulation - 2020 award open for entries for a chance to win €50,000 - - Investigator Award recognises individuals making a difference and reinforces company's ongoing commitment to the science of immunomodulation through ECP and its therapeutic applications - …